Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). | MicrobiomeTrials
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-09-20Est. Completion: 2029-07
Enrollment target: 25 participants
Locations
HM Monteprincipe, Boadilla del Monte, Madrid, Spain
Localized Clear Cell Renal Cell CarcinomaResectable Clear Cell Renal Cell CarcinomaStage II Renal Cell Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
This phase II trial studies how well ivonescimab works prior to surgery in treating patients with high-risk clear cell k…